US2004097722A9PendingUtilityA9
Preparation of phosphorothioate oligomers
Est. expiryOct 20, 2015(expired)· nominal 20-yr term from priority
C07F 9/65846C07H 9/04C07H 9/06C07F 9/1411C07H 19/10C07H 21/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and intermediates for the preparation of oligomers containing diastereomerically enriched phosphorothioate linkages are disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for synthesizing an oligomer having a phosphorothioate linkage comprising the steps of:
reacting a first synthon of Formula I:
wherein:
Q is independently O or S;
R 1 is a hydroxyl protecting group;
R 2 is a chiral auxiliary of formula —C(R 8 )R 3 —C(R 16 )R 5 —CHR 6 —NHR 7 ;
R 3 is hydrogen, alkyl, cyanomethyl, monohalomethyl, dihalomethyl, trigalomethyl, —CH 2 Si(R 4 ) 3 , or —CH 2 —SO k R 4 where k is 0, 1 or 2;
R 4 is independently alkyl, aryl, aralkyl or alkaryl having up to 15 carbon atoms;
R 5 is H, —CN, —Si(R 4 ) 3 , SO k R 4 or halogen;
or R 8 and R 16 are each H, and R 3 and R 5 , together, form one of the structures
wherein:
R 10 and R 11 are H, alkyl having from 1 to about 10 carbons, —CH 2 C(═O)OR 22 , —CH 2 CN, —CH 2 Si(CH 3 ) 3 , or o- or p-C 6 H 4 —R 21 ;
R 21 is hydrogen, —O—C(═O)CH 3 , alkoxy having from 1 to about 10 carbons, —NO 2 , or —N(R 22 ) 2 ;
R 22 is independently H or alkyl having from one to about 10 carbon atoms;
p is 1 or 2;
Z 1 and Z 2 are independently halogen, CN, —Si(CH 3 ) 3 , and —C(═O)OR 22 ;
R 30 is hydrogen, —O—C(═O)CH 3 , alkoxy having from 1 to about 10 carbons, or —O—Si(R 4 ) 3 ;
R 6 is H, alkyl or aralkyl having up to 15 carbon atoms;
or R 5 and R 6 , together with the atoms to which they are attached, form a 5 or 6 membered ring;
R 7 is alkyl or aralkyl having up to 15 carbon atoms;
or R 6 and R 7 , together, form one of the structures
wherein V, T, and Z are independently CH or N; R 8 is H or methyl; R 16 is H, alkyl or aralkyl having up to 15 carbon atoms; B a is a nucleobase; and n is an integer from 0 to 50;
with a second synthon of Formula II:
wherein:
R 9 is a hydroxyl protecting group or a linker connected to a solid support; and
m is an integer from 0 to 50; for a time and under reaction conditions effective to form a third synthon of Formula III:
and
contacting said third synthon with a sulfurizing agent to form an oligomer of Formula IV:
wherein D is said phosphorothioate linkage having the formula:
2 . The method of claim 1 wherein said phosphorothioate linkage is diastereomerically enriched.
3 . The method of claim 1 wherein about 75% of said phosphorothioate linkage is in a single stereoisomeric form.
4 . The method of claim 1 wherein about 85% of said phosphorothioate linkage is in a single stereoisomeric form.
5 . The method of claim 1 wherein about 95% of said phosphorothioate linkage is in a single stereoisomeric form.
6 . The method of claim 1 wherein said phosphorothioate linkage is in a single stereoisomeric form, substantially free of other stereoisomeric forms.
7 . The method of claim 1 wherein n is 0.
8 . The method of claim 1 wherein said first synhon is in a single stereoisomeric form, substantially free of other stereoisomeric forms.
9 . The method of claim 1 further comprising removing said R 1 group from said phosphorothioate.
10 . The method of claim 1 further comprising removing said chiral auxiliaries.
11 . The method of claim 1 wherein said compound of Formula IV contains a plurality of said phosphorothioate linkages.
12 . The method of claim 1 wherein said first and second synthons are reacted at a temperature of from about −20° C. to about 40° C.
13 . The method of claim 1 wherein said first and second synthons are reacted at a temperature of from about −15° C. to about 0° C.
14 . The method of claim 1 wherein said first synthon is formed by reacting a compound of Formula V:
with an azaphospholane of Formula VIa:
wherein R 3 -R 8 are as defined above; and X is halogen, dialkylamino, inidazols, triazole or substituted phenoxy wherein said substituents are electron withdrawing.
15 . The method of claim 14 wherein said electron withdrawing substituents are halogen or nitro.
16 . The method of claim 14 wherein said azaphospholane is produced by reacting a reagent of formula HO—C(R 8 )R 3 —C(R 16 )R 5 —CHR 6 —NHR 7 and a phosphorus trihalide, phosphorus tri(dialkylamide), phosphorus triphenoxide, or phosphorus tri(imidazolides).
17 . The method of claim 1 wherein said first synthon is formed by reacting a compound of Formula VII:
and a γ-amino alcohol of formula HO—C(R 8 )R 3 —C(R 16 )R 5 —CHR 6 —NHR 7 ; wherein X and R 1 -R 8 and R 16 are as defined above.
18 . The method of claim 17 wherein X is chlorine.
19 . The method of claim 17 wherein said reaction is stereoselective.
20 . The method of claim 18 wherein said first synthon is in a single stereoisomeric form, substantially free of other stereoisomeric forms.
21 . The method of claim 1 wherein'said reaction is performed in the presence of a catalyst.
22 . The method of claim 21 wherein said catalyst has one of the Formulas VIII or IX:
wherein:
R 12 and R 13 are independently hydrogen, halogen, cyano, nitro, alkyl having from one to 10 carbons, substituted alkyl having from one to 10 carbons, and ester group, or R 12 and R 13 together with the carbon atoms to which they are attached, form a substituted or unsubstituted phenyl ring where said substituents are electron withdrawing; and
R 14 is hydrogen, halogen, cyano, nitro, thio, alkyl having from one to 10 carbons, substituted alkyl having from one to 10 carbons, norbornyl, substituted norbornyl, aryl, substituted aryl wherein said substituents are electron withdrawing, or has the formula:
wherein L is protecting group.
23 . The method of claim 21 wherein R 14 is halogen or nitro, and wherein R 12 and R 13 are each halogen or each cyano.
24 . The method of claim 22 wherein R 14 is bromine, and R 12 and R 13 are each cyano.
25 . The method of claim 22 wherein R 14 , R 12 and R 13 are each bromo.
26 . The method of claim 21 wherein R 14 has one of the formulas:
wherein R 15 is H, methyl, trialkylsilyl or acetyl.
27 . The method of claim 1 wherein R 3 is cyanomethyl or —CH 2 —SO k R 4 where k is 0, 1 or 2.
28 . The method of claim 27 wherein R 7 is lower alkyl or aralkyl.
29 . The method of claim 1 wherein said first synthon has one of the Formulas Xa, XIa, XIIa, XIIIa or XXa:
wherein W has the formula:
and R 1 -R 16 , V, T and Z are as defined above.
30 . The method of claim 29 wherein said first synthon has the Formula Xb or Xc:
31 . The method of claim 29 where;n said first synthon has the Formula XIVa:
wherein p, Z 1 and Z 2 are as defined above.
32 . The method of claim 31 wherein said first synthon has the Formula XVa or XVIa:
wherein Y, R 7 , Z 1 , Z 2 , and p are as defined above.
33 . The method of claim 29 wherein said first synthon has the Formula XVIIa or XVIIIa:
wherein W, R 7 , R 10 and R 11 are as defined above.
34 . The method of claim 1 further comprising removing said R 9 groups.
35 . The method of claim 1 further comprising removing said R 2 groups.
36 . The oligomer produced by the method of claim 1 .
37 . An azaphospholane of Formula VIb:
wherein:
y is X or W wherein X is halogen, dialkylamino, imidazole, triazole or substituted phenoxy wherein said substituents are electron withdrawing, and W has the formula:
wherein:
Q is independently O or S;
R 1 is a hydroxyl Protecting group;
R 2 is a chiral auxiliary of formula —C(R 8 )R 3 —C(R 16 )R 5 —CHR 6 —NHR 7 ;
R 3 is hydrogen, alkyl, cyanomethyl, monohalomethyl, dihalomethyl, trihalomethyl, —CH 2 Si(R 4 ) 3 , or —CH 2 —SO k R 4 where k is 0, 1 or 2;
R 4 is independently alkyl, aryl, aralkyl or alkaryl having up to 15 carbon atoms;
R 5 is H, —CN, —Si(R 4 ) 3 , SO k R 4 or halogen;
or R 8 and R 16 are each H, and R 3 and R 5 , together, form one of the structures
wherein:
R 10 and R 11 are H, alkyl having from 1 to about 10 carbons, —CH 2 C(═O)OR 22 , —CH 2 CN, —CH 2 Si(CH 3 ) 3 , or o- or p-C 6 H 4 —R 21 ;
R 21 is hydrogen, —O—C(═O)CH 3 , alkoxy having from 1 to about 10 carbons, —NO 2 , or —N(R 22 ) 2 ;
R 22 is independently H or alkyl having from one to about 10 carbon atoms;
p is 1 or 2;
Z 1 and Z 2 are independently halogen, CN, —Si(CH 3 ) 3 , and —C(═O)OR 22 ;
R 30 is hydrogen, —O—C(═O)CH 3 , alkoxy having from 1 to about 10 carbons, or —O—Si(R 4 ) 3 ;
R 6 is H, alkyl or aralkyl having up to 15 carbon atoms;
or R 5 and R 6 , together with the atoms to which they are attached, form a 5 or 6 membered ring;
R 7 is alkyl or aralkyl having up to 15 carbon atoms;
or R 6 and R 7 , together, form one of the structures
wherein X, T, and Z are independently CH or NH; or Z and R 5 , together with the atoms to which they are attached, form a phenyl ring;
R 8 is H or methyl;
R 9 is a hydroxyl protecting group or a solid support;
R 16 is H, alkyl or aralkyl having up to 15 carbon atoms;
B is a nucleobase; and
n is an integer from 0 to 50.
38 . The azaphospholane of claim 37 wherein Y is W and n is 0.
39 . The azaphospholane of claim 37 wherein Y is halogen.
40 . The azaphospholane of claim 37 wherein Y is chlorine.
41 . The azaphospholane of claim 37 wherein R 7 is alkyl.
42 . The azaphospholane of claim 37 wherein R 7 R 6 and the atoms to which they are attached form a 5 or 6 membered ring.
43 . The azaphospholane of claim 38 wherein R 3 is cyanomethyl or —CH 2 —SO k R 6 where k is 0, 1 or 2.
44 . The azaphospholane of claim 37 having one of the Formulas XVIc or XVId:
45 . The azaphospholane of claim 36 having one of the Formulas Xb, XIb, XIIb, XIIIb or XXb:
wherein R 3 -R 16 , Y, V, T, Z, Z 1 , Z 2 and p are as defined above.
46 . The azaphosphalane of claim 45 having the Formula XIVb:
wherein Y, R 6 , R 7 , R 8 , p, Z 1 and Z 2 are as defined above.
47 . The azaphosphalane of claim 44 having the Formula Xd or Xe:
wherein Y, R 3 , R 5 , R 8 , and R 1 6 are as defined above.
48 . The azaphospholane of claim 45 having the Formula XVIIb or XVIIIb.
wherein Y, R 7 , R 10 and R 11 are as defined above.
49 . The azaphospholane of claim 45 having the Formula XVb or XVIb:
wherein Y, R 7 , Z 1 , Z 2 , and p are as defined above.
50 . The azaphospholane of claim 37 wherein said azaphospholane is diastereomerically enriched.
51 . The azaphospholane of claim 37 wherein 75% of said azaphospholane is in a single stereoisomeric form.
52 . The azaphospholane of claim 37 wherein 85% of said azaphospholane is in a single stereoisomeric form.
53 . The azaphospholane of claim 37 wherein 95% of said azaphospholane is in a single stereoisomeric form.
54 . The azaphospholane of claim 37 wherein said azaphospholane is in a single stereoisomeric form, substantially free of other stereoisomeric forms.
55 . An oligomeric compound comprising a moiety having a phosphite linkage of the Formula XXX:
wherein:
R 3 is hydrogen, alkyl, cyanomethyl, monohalomethyl, dihalomethyl, trihalomethyl, —CH 2 Si(R 4 ) 3 , or —CH 2 —SO k R 4 where k is 0, 1 or 2;
R 4 is independently alkyl, aryl, aralkyl or alkaryl having up to 15 carbon atoms;
R 5 is H, —CN, —Si(R 4 ) 3 , SO k R 4 or halogen;
or R 8 and R 16 are each H, and R 3 and R 3 , together, form one of the structures
wherein:
R 10 and R 11 are H, alkyl having from 1 to about 10 carbons, —CH 2 C(═O)OR 22 , —CH 2 CN, —CH 2 Si(CH 3 ) 3 , or o- or p-C 6 H 4 —R 21 ;
R 21 is hydrogen, —O—C(═O)CH 3 , alkoxy having from 1 to about 10 carbons, —NO 2 , or —N(R 22 ) 2 ;
R 22 is independently H or alkyl having from one to about 10 carbon atoms;
p is 1 or 2;
Z 1 and Z 2 are independently halogen, CN, —Si(CH 3 ) 3 , and —C(═O)OR 22 ;
R 30 is hydrogen, —O—C(═O)CH 3 , alkoxy having from 1 to about 10 carbons, or —O—Si(R 4 ) 3 ;
R 6 is H, alkyl or aralkyl having up to 15 carbon atoms;
or R 5 and R 6 , together with the atoms to which they are attached, form a 5 or 6 membered ring;
R′ is alkyl or aralkyl having up to 15 carbon atoms;
or R 6 and R 7 , together, form one of the structures
wherein X, T, and Z are independently CH or NH; or Z and R 5 , together with the atoms to which they are attached, form a phenyl ring;
R 8 is H or methyl;
R 9 is a hydroxyl protecting group or a solid support;
R 16 is H, alkyl or aralkyl having up to 15 carbon atoms;
B is a nucleobase; and
n is an integer from 0 to 50.
56 . The oligomeric compound of claim 55 wherein 75% of said phosphosphite linkage is in a single stereoisomeric form.
57 . The oligomeric compound of claim 55 wherein 85% of said phosphosphite linkage is in a single stereoisomeric form.
58 . The oligomeric compound of claim 55 wherein 95% of said phosphosphite linkage is in a single stereoisomeric form.
59 . The oligomeric compound of claim 55 wherein said phosphosphite linkage is in a single stereoisomeric form, substantially free of other stereoisomeric forms.Join the waitlist — get patent alerts
Track US2004097722A9 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.